Free tool
FAERS Monitor: Corlanor
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206143 or its brand name (Corlanor, Ivabradine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
6,950
Serious
5,003
72% of reports
Hospitalization
2,513
Death reported
532
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,369
- dyspnoea478
- hypotension450
- dizziness366
- cardiac failure347
- fatigue342
- drug interaction332
- drug ineffective302
- nausea276
- bradycardia258
- headache251
- chest pain206
- malaise194
- palpitations182
- oedema peripheral170
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 5 |
| 2009 | 6 |
| 2010 | 11 |
| 2011 | 21 |
| 2012 | 42 |
| 2013 | 55 |
| 2014 | 105 |
| 2015 | 336 |
| 2016 | 683 |
| 2017 | 603 |
| 2018 | 582 |
| 2019 | 546 |
| 2020 | 610 |
| 2021 | 574 |
| 2022 | 663 |
| 2023 | 529 |
| 2024 | 575 |
| 2025 | 610 |
| 2026 | 393 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,209 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bradycardiaSignal | 258 | 14.8 | 13.1 | 3,297 |
| cardiac failureSignal | 347 | 13.1 | 11.9 | 3,876 |
| hypotensionSignal | 450 | 6.8 | 6.2 | 2,238 |
| drug interactionSignal | 332 | 6.3 | 5.7 | 1,498 |
| off label useSignal | 1,369 | 4.7 | 4.5 | 4,201 |
| palpitationsSignal | 182 | 4.7 | 4.1 | 530 |
| oedema peripheralSignal | 170 | 4.2 | 3.6 | 417 |
| chest painSignal | 206 | 3.4 | 2.9 | 343 |
| dyspnoeaSignal | 478 | 2.6 | 2.3 | 464 |
| dizzinessSignal | 366 | 2.2 | 2.0 | 250 |
| malaise | 194 | 1.3 | 1.2 | 17 |
| fatigue | 342 | 1.3 | 1.2 | 29 |
| headache | 251 | 1.2 | 1.1 | 9 |
| nausea | 276 | 1.1 | 0.9 | 1 |
| drug ineffective | 302 | 0.7 | 0.6 | 43 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.